What is "Ozempic face," and can I prevent it?

The face contains several distinct fat compartments — the buccal (cheek) fat pad, the malar (cheekbone) pad, and the temporal (temple) pad among them. In young adults these compartments are plump and taut against the skin; with weight loss they shrink, and the face's underlying bony structure becomes more visible.

The change looks dramatic on GLP-1s for two reasons. First, the total weight loss is larger than most diets deliver — 15–21% of body weight in trials — and facial fat is lost roughly in proportion to total body fat. Second, the loss happens fast (over months rather than years), giving skin less time to retract. Skin elasticity declines from the mid-30s onward, so the effect is more visible in adults over 40 than in younger patients losing the same amount of weight.

It is not a drug-specific side effect. The same facial change happens with any substantial, rapid weight loss — bariatric-surgery patients report the identical phenomenon, and dermatology literature described it long before GLP-1s were widely prescribed. What GLP-1s did was scale up the number of people experiencing it.

There are three levers you can pull to reduce it. Slowing the pace of loss (aim for ~0.5–1% body weight per week rather than 2%+) gives skin time to remodel. Protecting muscle mass (see muscle-loss above) helps because a large fraction of facial fullness comes from underlying facial musculature, not just fat. And if the appearance still concerns you at goal weight, dermatologic options — hyaluronic-acid fillers, biostimulators (Sculptra), or, for the buccal pad specifically, careful volumizing — restore volume without reversing the weight loss.